Baseline PSA levels in midlife & future development of lethal prostate cancer: A diverse North American cohort analysis

被引：0
|
作者：
Davis, M. [1 ]
Stephens, A. [1 ]
Morrison, C. [1 ]
Majdalany, S. [1 ]
Affas, R. [1 ]
Arora, S. [1 ]
Corsi, N. [1 ]
Rakic, I [1 ]
Sood, A. [2 ]
Rogers, C. [1 ]
Abdollah, F. [1 ]
机构：
[1] Henry Ford Hlth Syst, Vattikuti Urol Inst, Detroit, MI USA
[2] MD Anderson, Dept Urol, Houston, TX USA
来源：
EUROPEAN UROLOGY | 2023年 / 83卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
A0258
引用
收藏
页码：S367 / S367
页数：1
相关论文
共 50 条
  • [21] PSA levels within 2 years of diagnosis do not predict lethal prostate cancer outcomes
    Nature Clinical Practice Urology, 2007, 4 (7): : 351 - 352
  • [22] Evolution of PSA levels in first degree relatives of prostate cancer patients, with baseline PSA <=1ng/ml
    Valeri, A
    Moineau, MP
    Joulin, V
    Azzouzi, R
    Cormier, L
    Mangin, P
    Cussenot, O
    Morin, JF
    Fournier, G
    JOURNAL OF UROLOGY, 2004, 171 (04): : 121 - 122
  • [23] Longitudinal cohort analysis of lethal prostate cancer progression in transgenic mice
    Hsu, CX
    Ross, BD
    Chrisp, CE
    Derrow, SZ
    Charles, LG
    Pienta, KJ
    Greenberg, NM
    Zeng, Z
    Sanda, MG
    JOURNAL OF UROLOGY, 1998, 160 (04): : 1500 - 1505
  • [24] Prostate Cancer Development Is Not Affected by Statin Use in Patients with Elevated PSA Levels
    Meijer, Dennie
    van Moorselaar, R. Jeroen A.
    Vis, Andre N.
    Bijnsdorp, Irene, V
    CANCERS, 2019, 11 (07)
  • [25] No observation of racial differences in serum prostate-specific antigen (PSA) levels and PSA densities in a cohort of clinically localized African-American and Caucasian prostate cancer patients presenting for radiotherapy
    Tekyi-Mensah, S
    Keole, SR
    Dey, J
    Bolton, S
    Forman, JD
    RADIOLOGY, 2002, 225 : 320 - 320
  • [26] Combining SERS analysis of serum with PSA levels for improving the detection of prostate cancer
    Stefancu, Andrei
    Moisoiu, Vlad
    Couti, Razvan
    Andras, Iulia
    Rahota, Razvan
    Crisan, Dana
    Pavel, Ioana E.
    Socaciu, Carmen
    Leopold, Nicolae
    Crisan, Nicolae
    NANOMEDICINE, 2018, 13 (19) : 2455 - 2467
  • [27] The effect of body mass index on PSA levels and the development, screening and treatment of prostate cancer
    Ted A Skolarus
    Kathleen Y Wolin
    Robert L Grubb
    Nature Clinical Practice Urology, 2007, 4 : 605 - 614
  • [28] The effect of body mass index on PSA levels and the development, screening and treatment prostate cancer
    Skolarus, Ted A.
    Wolin, Kathleen Y.
    Grubb, Robert L., III
    NATURE CLINICAL PRACTICE UROLOGY, 2007, 4 (11): : 605 - 614
  • [29] Performance of prostate health index and PSA density in a diverse biopsy-naïve cohort with mpMRI for detecting significant prostate cancer
    Carbunaru, Samuel
    Stinson, James
    Babajide, Rilwan
    Hollowell, Courtney M. P.
    Yang, Ximing
    Sekosan, Marin
    Ferrer, Karen
    Kajdacsy-Balla, Andre
    Abelleira, Josephine
    Ruden, Maria
    King-Lee, Patrice
    Dalton, Daniel P.
    Casalino, David D.
    Kittles, Rick A.
    Gann, Peter H.
    Schaeffer, Edward M.
    Murphy, Adam B.
    BJUI COMPASS, 2021, 2 (06): : 370 - 376
  • [30] PROSTATE-SPECIFIC ANTIGEN (PSA) LEVELS IN MEN AGED 60 TO 70 AND DEVELOPMENT OF LETHAL PROSTATE CANCER OVER 30 YEARS: IMPLICATIONS FOR RISK-STRATIFIED SCREENING
    Preston, Mark
    Downer, Mary Kathryn
    Gerke, Travis
    Carlsson, Sigrid
    Sesso, Howard
    Kibel, Adam
    Trinh, Quoc-Dien
    Lilja, Hans
    Vickers, Andrew
    Wilson, Kathryn
    Mucci, Lorelei
    JOURNAL OF UROLOGY, 2017, 197 (04): : E487 - E488
12345